Abstract: A disposable isolation gown including a body covering layer comprising a first portion, a second portion, a first sleeve and a second sleeve. The disposable isolation gown includes a head insertion aperture defined by the body covering layer, wherein the head insertion aperture is disposed between the first portion and the second portion, and adjacent to the first sleeve and the second sleeve. The disposable isolation gown includes a perforation extending vertically along the second portion of the body covering layer.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups ring A and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups ring A and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1-R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: A method or a machine determines minimum (s) and maximum (S) inventory control levels (s, S) for inventory items based upon a demand history of the inventory items, such as demand inter-arrival times (IA) and demand requisition sizes (RS). An expected cost is computed including two or more inventory item cost components of expected cost of ordering, expected cost of carrying inventory, or expected cost of outstanding backorders for the inventory control levels (s, S), directly from frequency statistics of different demand IA and demand RS on an inventory item basis. An optimal inventory control level (s, S) of an inventory item is searched that minimizes the cost of ordering, carrying inventory, and/or backorders, based upon the generated expected cost.

Abstract: The present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, R7 and p are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1-R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, R7 and p are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: A method or a machine determines minimum (s) and maximum (S) inventory control levels (s, S) for inventory items based upon a demand history of the inventory items, such as demand inter-arrival times (IA) and demand requisition sizes (RS). An expected cost is computed including two or more inventory item cost components of expected cost of ordering, expected cost of carrying inventory, or expected cost of outstanding backorders for the inventory control levels (s, S), directly from frequency statistics of different demand IA and demand RS on an inventory item basis. An optimal inventory control level (s, S) of an inventory item is searched that minimizes the cost of ordering, carrying inventory, and/or backorders, based upon the generated expected cost.

Abstract: A non-expanding bullet platform may comprise a modular jacket having an internal nose cavity and an internal heel cavity. The cavities may be separated by a divider. The cavities may be filled with suitable materials to produce various types of non-expanding bullets, such as military ball, trace, armor piercing, etc. Inventive non-expanding bullets may comprise full metal jacketed bullets or may have exposed material. The inventive bullets may be non-expanding, wherein the diameter of the bullet does not substantially increase upon impacting soft tissue.

Abstract: The present invention is drawn to a composition comprising abrasive particles comprising an organic resin for chemical mechanical planarization (CMP), which can be widely used in the semiconductor industry. The abrasive composition is an aqueous slurry comprising abrasive particles comprising an organic resin, wherein the slurry is held at a pH in the range of 2-12. An attractive feature of the inventive abrasive composition is that it can be tailored to selectively remove different components from the surface. The inventive abrasive composition also provides efficient polishing rates and good surface quality when used in CMP applications.

Abstract: The present invention is drawn to a composition comprising abrasive particles comprising an organic resin for chemical mechanical planarization (CMP), which can be widely used in the semiconductor industry. The abrasive composition is an aqueous slurry comprising abrasive particles comprising an organic resin, wherein the slurry is held at a pH in the range of 2-12. An attractive feature of the inventive abrasive composition is that it can be tailored to selectively remove different components from the surface. The inventive abrasive composition also provides efficient polishing rates and good surface quality when used in CMP applications.